R.H. Bluestein & Co’s Medicines Co MDCO Stock Holding History

R.H. Bluestein & Co’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,180	Closed	-$209K	–	379
2019 Q3	$209K	Sell	4,180 -26,870	-87%	-$1.07M	0.01%	307
2019 Q2	$1.13M	Buy	+31,050	New	+$1.01M	0.06%	66
2018 Q4	–	Sell	-43,925	Closed	-$1.31M	–	326
2018 Q3	$1.31M	Sell	43,925 -38,675	-47%	-$1.46M	0.06%	68
2018 Q2	$3.03M	Buy	+82,600	New	+$2.68M	0.16%	44

Other funds holding MDCO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

R.H. Bluestein & Co's MDCO Position: Q4 2019 in Review

R.H. Bluestein & Co sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 4,180 shares — an estimated $209K sold.

R.H. Bluestein & Co first reported a position in MDCO in Q2 2018 and held it in 4 quarters. The position peaked at $3.03M in Q2 2018. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

R.H. Bluestein & Co reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
R.H. Bluestein & Co sold 4,180 Medicines Co shares in Q4 2019, an estimated $209K.
R.H. Bluestein & Co first reported a position in Medicines Co in Q2 2018 and held it in 4 quarters.
R.H. Bluestein & Co's Medicines Co position peaked at $3.03M in Q2 2018.
284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on R.H. Bluestein & Co's 13F filing for Q4 2019, filed 13 Feb 2020.